Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

krka, d.d., novo mesto, slovinsko - rosuvastatín - 31 - hypolipidaemica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

medreg s.r.o., Česká republika - bisoprolol - 41 - cardiaca

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

medreg s.r.o., Česká republika - bisoprolol - 41 - cardiaca

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

medreg s.r.o., Česká republika - bisoprolol - 41 - cardiaca

Európska únia - slovenčina - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinúria, paroxysmálna - selektívne imunosupresíva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

fujifilm corporation 26-30 nishiazabu 2-chome, minato-ku 106-8620 tokyo japonsko -

Slovensko - slovenčina - Ústav štátnej kontroly veterinárnych biopreparátov a liečiv

elanco gmbh, nemecko - tbl.

Európska únia - slovenčina - EMA (European Medicines Agency)

novartis europharm limited  - siponimod fumaric kyseliny - roztrúsená skleróza, recidivujúce-odosielajúcej - selektívne imunosupresíva - mayzent je indikovaný na liečbu dospelých pacientov so sekundárne progresívnou roztrúsená skleróza (spms) aktívne ochorenie potvrdené recidív alebo zobrazovacie funkcie zápalových činnosť.

Slovensko - slovenčina - Ústav štátnej kontroly veterinárnych biopreparátov a liečiv

bioveta, Česká republilka - tbl.

Slovensko - slovenčina - Ústav štátnej kontroly veterinárnych biopreparátov a liečiv

bioveta, Česká republilka - tbl.